SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending as traders discuss its potential for a short squeeze and speculate on price movements, with some expressing concerns about it being a pump and dump. The stock's low float and recent volatility are key points of discussion, with community members comparing it to other robotics plays. Some traders are also eyeing related tickers, anticipating similar potential moves.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim results from its RAD 101 brain metastases imaging trial, showing high accuracy. Community discussions revolve around the potential for a short squeeze and the company's cash runway extending into 2026, while some traders express concern about potential dilution and the stock's volatility within the oncology sector.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending amid discussions of a potential short squeeze, fueled by its low float and recent price surges, leading to multiple trading halts. The community is actively debating entry and exit points, comparing it to other low-float runners, and anticipating a possible breakout if it surpasses key resistance levels. Some traders caution about potential dilution given the company's structure.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst community frustration over its persistent underperformance, with many questioning its utility and comparing it unfavorably to other cryptocurrencies. Discussions include concerns about potential scams, the team's leadership, and its inability to rally with the broader market, though some bulls remain hopeful for future developments and adoption in Japan. The recent price action has led to increased speculation and calls for strategic shifts.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending amid discussions about data center demand, AI's potential bubble status, and recent price declines. The community is debating the stock's valuation, potential for long-term growth, and its sensitivity to Bitcoin's price movements, with some expressing concerns about market manipulation and short-term volatility in the sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid discussions about its AI and autonomous driving progress, particularly the testing of driverless robotaxis. Community talking points include the potential impact of a SpaceX IPO on Tesla's valuation, as well as debates over the company's current valuation relative to its sales and profit figures. Some traders are also noting technical indicators suggesting a possible breakout.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community debates its future amid mixed signals and a sideways trading pattern, despite Ripple's positive developments and new banking license approval; skepticism persists with some traders expressing frustration over unrealized gains, while others remain optimistic about long-term potential driven by institutional adoption and upcoming regulatory clarity.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as investors discuss the company's recent announcement of preliminary data from its FLAMINGO-01 trial, which showed a significant reduction in breast cancer recurrence rates, sparking optimism about the potential of GLSI-100 immunotherapy; however, some traders believe shares are being surpressed. The community is actively debating the implications of these results, potential buyout scenarios, and the stock's future trajectory.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending due to discussions around its low float and potential for a short squeeze, with comparisons being made to past runners like $SMX and $ARBB. Traders are closely watching for a breakout, with key price levels around $6.5 and $8 being mentioned as potential catalysts for a significant move. Some anticipate upcoming earnings could further fuel upward momentum.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending downwards, sparking debates about averaging down and the health of the data center trade. Community members are attributing the price drop to institutional repositioning or short pressure, while others remain confident in the company's fundamentals and future contracted revenue, viewing it as a buying opportunity amidst market volatility. Some traders are expressing frustration and hoping for news regarding a hyperscaler tenant to turn things around.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CERo Therapeutics Holdings (CERO) announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CERO">CERO stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_10_32_53_AM_png_e724743b98.webp" alt="CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="64"><figcaption>CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects a "big bounce" for the stock soon.<stembedurl>https://stocktwits.com/pharmdavid13/message/627619560</stembedurl>FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=6780690611361163">said</a>.The new designation comes weeks after the FDA granted the experimental drug an Orphan Drug designation. The FDA's Orphan Drug program is designed to advance the development of drugs that treat rare conditions affecting 200,000 or fewer US patients annually.“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable,” said CERo Therapeutics CEO Chris Ehrlich.The company is currently undertaking early-stage trials of CER-1236 in patients with acute myeloid leukemia. The study is designed to evaluate the safety and preliminary efficacy of the experimental cancer drug.Shares of the company, however, slumped 12% at the time of writing after the firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1870404/000121390025084610/ea025606902-424b3_cero.htm">said</a> on Thursday that it recently received a letter from the Nasdaq Listing Qualifications department notifying the company that it does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market.The Nasdaq staff indicated that the company’s securities would be suspended from trading on Nasdaq and delisted on Sept. 8, 2025. The company said that it subsequently requested a hearing to appeal the determination before a panel. The hearing request will stay the suspension of the trading of the company’s common stock and delisting thereof pending such hearing, it said.The company said that it intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement at the hearing. Such a plan of compliance may include an increase in stockholders’ equity through the consummation of public or private financing transactions, the company said, while adding that there can be no assurances that it will obtain a favorable decision from the hearing panel.CERO stock is down by 95% this year and by 97% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.

Equity

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.


Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML).The stock soared 189% to $19.83&nbsp;in the regular session, but fell by 15% in after-hours trading.The Phase 1/1b, open-label, multi-center clinical trial will assess the safety and initial efficacy of CER-1236 in patients with relapsed or refractory AML, remission with measurable residual disease, or newly diagnosed with TP53-mutated MDS/AML or AML.The study will include a dose escalation to determine the recommended Phase 2 dose and an expansion phase.Major objectives include the frequency of adverse events, dose-limiting toxicities, estimated overall and complete response rates, and measurable residual disease. Minor objectives include pharmacokinetics.The company said CER-1236 is designed to engineer a patient’s T cells to use phagocytic mechanisms — or target-cell “eating” — in addition to T cell destruction mechanisms.The Orphan Drug designation includes FDA assistance in clinical trial design, grants, a waiver of drug application fees, and seven years of market exclusivity upon approval.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they had accumulated shares from $8 to $15 and were still holding 4,700 shares, undecided on whether to carry the position overnight.&nbsp;<stembedurl>https://stocktwits.com/Dansaidso/message/618224240</stembedurl>Another user pointed to the stock's sharp gains, suggesting that after-hours moves were less meaningful for low-float names like Cero, which they believed could see additional upside.<stembedurl>https://stocktwits.com/SK444/message/618231176</stembedurl>Cero stock has declined 83.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

CER-1236 is designed to engineer T cells with phagocytic, or target-cell "eating," functions alongside traditional cancer-killing mechanisms. 

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7625589476402466">announced</a> an agreement with the University of California Davis to manufacture its lead compound, CER-1236, which will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia (AML).The company said that the first patient is expected to be dosed in the first half of 2025.CEO Chris Ehrlich highlighted UC Davis’ precision and compliance in manufacturing, which is critical for the successful development and execution of clinical trials.“The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward,” he said.The U.S. Food and Drug Administration (FDA) cleared the company’s application for phase 1 clinical trials of the compound in November.Earlier this month, during a scientific conference in San Diego, the company demonstrated that CER-1236 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=5472816266845157">treated</a> ovarian cancer cells without generating toxicity in animals.On Stocktwits, retail sentiment continues to trend in the ‘bullish’ territory (63/100) while message volume remains high.<figure class="image"><img style="aspect-ratio:811/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_101142_png_18b82101f9.webp" alt="CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="177"><figcaption>CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>At the end of 2024, the company faced delisting risks after its shares traded below Nasdaq’s minimum bid price requirement. Earlier this year, it announced a one-for-hundred reverse stock split of its common stock to increase its market price.In February, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7680160497345168">raised $5 million</a> through a public offering.<a href="https://stocktwits.com/symbol/CERO">Shares of CERo</a> have dropped by over 80% year-to-date and about 100% in the past 12 months. On Wednesday morning, the stock opened over 2% lower.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish

The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

CERO
CERo Therapeutics Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CERO News

CEROCERo Therapeutics Holdings Inc